Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients

Next-Generation Cancer Vaccine Approaches: Integrating Lessons Learned From Current Successes With Promising Biotechnologic Advances

(2017) Dung T. Le et al.   Journal of the National Comprehensive Cancer Network

Glucosylceramide synthase inhibitors D-PDMP and D-EtDO-P4 decrease the GM3 ganglioside level, differ in their effects on insulin receptor autophosphorylation but increase Akt1 kinase phosphorylation in human hepatoma HepG2 cells

(2016) Natalia Fedoryszak-Kuśka et al.   ACTA BIOCHIMICA POLONICA

Racotumomab for treating lung cancer and pediatric refractory malignancies

(2016) Mariano R. Gabri et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation

(2016) Qian Gong et al.   mAbs

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions

(2015) Xiao X Wei et al.   Expert Review of Vaccines

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

(2015) Wei Wang   Frontiers in Immunology

Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro

(2015) Jennifer D. Könitzer et al.   PLoS One

Classification of current anticancer immunotherapies

(2015) Lorenzo Galluzzi et al.   Oncotarget

The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases

(2015) Vinochani Pillay et al.   NEOPLASIA

Immunoreactivity of the 14F7 Mab raised againstN-Glycolyl GM3 Ganglioside in retinoblastoma tumours

(2014) Ana Vanesa Torbidoni et al.   ACTA OPHTHALMOLOGICA

A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

(2014) S. Alfonso et al.   CLINICAL CANCER RESEARCH

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

(2013) Holger N. Lode et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies

(2013) Ursula J. E. Seidel et al.   Frontiers in Immunology

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Alfons JM van den Eertwegh et al.   LANCET ONCOLOGY

Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer

(2012) Valeria I. Segatori et al.   Frontiers in Oncology

Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer

(2011) Alejandra M. Scursoni et al.   Clinical & Developmental Immunology

Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo

(2011) Markus Biburger et al.   IMMUNITY

Anti-NeuGcGM3 Antibodies, Actively Elicited by Idiotypic Vaccination in Nonsmall Cell Lung Cancer Patients, Induce Tumor Cell Death by an Oncosis-Like Mechanism

(2011) A. M. Hernandez et al.   JOURNAL OF IMMUNOLOGY

Cancer immunotherapy – revisited

(2011) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

Antibodies in oncology

(2011) Vinochani Pillay et al.   New Biotechnology

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer

(2009) Hester van Cruijsen et al.   BMC CANCER

Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model

(2009) D. Fuentes et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

(2009) D. M. Jackman et al.   CLINICAL CANCER RESEARCH

Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines

(2009) Mariano R Gabri et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2009) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

(2008) Y. Diaz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function

(2008) J. de Leon et al.   INTERNATIONAL IMMUNOLOGY